Stereotactic Body Radiotherapy With or Without Darolutamide for OligoRecurrent Prostate Cancer: a Randomized Phase II Trial (DART)
Latest Information Update: 23 May 2024
At a glance
- Drugs Darolutamide (Primary)
- Indications Adenocarcinoma; Prostate cancer
- Focus Therapeutic Use
- Acronyms DART
- 26 Oct 2023 Planned number of patients changed from 124 to 140.
- 03 Feb 2023 Planned number of patients changed from 128 to 124.
- 25 Jan 2023 Planned End Date changed from 31 Dec 2024 to 12 Feb 2026.